(2) It reliably detected WHO-classified markers, including BRAF mutations in all hairy cell leukemia cases, MYD88/CXCR4 mutations in lymphoplasmacytic lymphoma, and absence of BRAF mutations in splenic B-cell lymphoma with prominent nucleoli. This evidence concerns the gene BRAF and lymphoplasmacytic lymphoma.